- Legg-Calve-Perthes disease, a rare pediatric orthopedic condition affecting the hip joint, is gaining increased attention due to advancements in diagnostic imaging and early-stage intervention. With a growing awareness among caregivers and medical professionals, the market is witnessing steady growth, particularly in developed nations, where early diagnosis leads to improved patient outcomes and reduced long-term disability
- The rising prevalence of childhood musculoskeletal disorders, coupled with increasing pediatric orthopedic consultations, is a primary driver of market growth for Legg-Calve-Perthes disease treatments worldwide
- North America dominated the Legg-Calve-Perthes disease market with the largest revenue share of 40.01% in 2024, attributed to the presence of specialized pediatric orthopedic centers, strong healthcare insurance penetration, and high parental awareness regarding developmental bone diseases. The U.S. in particular has experienced a rise in early screening and bracing therapies, supported by hospital-led awareness campaigns
- Asia-Pacific is expected to be the fastest-growing region in the Legg-Calve-Perthes disease market during the forecast period, due to increasing urbanization, improving access to pediatric care, and rising disposable incomes. Countries like China and India are expanding their pediatric orthopedic departments, supported by both public and private investments
- The non-surgical treatment segment dominated the Legg-Calve-Perthes disease market with a market share of 61.3% in 2024, driven by the widespread use of physiotherapy, bracing, and anti-inflammatory medications as first-line interventions. These approaches are particularly effective in early-stage cases and are commonly recommended for younger patients to manage symptoms and support hip joint recovery without surgical intervention
